Apicore US LLC

Rk Pharma Inc.

Rk Pharma Solutions LLC

Shivnath Sahebrao Patil

Ravishanker Kovi

Jayaraman Rao Kannapan

Jayaraman Kannappan

Sanjay F Thakor

Ananda Babu Thirunavakarasu

Ashish Naik

Veerabhadra Rao Bobbili

Gaurav Yadav

Chowdari Bhushaiah Talluri

Govind Ahirrao

Aditya Khanvilkar

Dhakhada Chetana Bharatbhai

Khichi Kuldip Fatehlal

The present application provides improved processes for the synthesis of eribulin intermediate, which generally comprise the steps of: a) De-protecting the eribulin-enone (compound 1) in tetrahydrofuran by using TBAF solution, buffered with imidazole HCl in the presence of molecular sieve and sodium sulphate to get an insitu mixture of eribulin-dione diastereomer at C12 carbon (compound 2). Then ketalization may be performed of eribulin-dione insitu intermediate containing mixture of diastereomer at C12 carbon (compound 2) with PPTS in dichloromethane to yield eribulin-diol (compound 3).

Process for the preparation of eribulin mesylate intermediate

A process for the preparation of hydroxocobalamin hydrochloride. More particularly the present application relates to improved process for the preparation of Hydroxocobalamin hydrochloride. In addition the present application also relates to process for the preparation of novel amorphous form. This application particularly relates to a process for the industrial manufacture of hydroxocobalamin hydrochloride from cyanocobalamin. The present application also relates to the improvement in yield with better purity of Hydroxocobalamin hydrochloride.

Process for the preparation of hydroxocobalamin hydrochloride

Novel crystalline ponatinib hydrochloride forms designated Form alpha and Form beta are disclosed. Form alpha is characterized by data selected from an XRPD pattern with peaks at about 6.5, 9.0, 12.25, 14.4, 16.70, 19.6, 22.2, 24.5, 28.2&#xb1;0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG.; and/or a combination thereof. Form beta is characterized by data selected from an XRPD pattern with peaks at about 10.7, 15.2, 15.8, 16.4 23.1, 25.0, 27.8&#xb1;0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG.; and/or combinations thereof. Processes for making Form alpha and Form beta are disclosed.

Polymorphs of ponatinib hydrochloride

Methods are disclosed for making 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide, intermediates and pharmaceutically acceptable salts thereof.

Processes for making ponatinib and intermediates thereof

Growing community of inventors

Maharashtra, India

Shivnath Sahebrao Patil